348 related articles for article (PubMed ID: 32064793)
1. Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling.
Sokolov V; Yakovleva T; Chu L; Tang W; Greasley PJ; Johansson S; Peskov K; Helmlinger G; Boulton DW; Penland RC
CPT Pharmacometrics Syst Pharmacol; 2020 Apr; 9(4):222-229. PubMed ID: 32064793
[TBL] [Abstract][Full Text] [Related]
2. Mechanistic evaluation of the effect of sodium-dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacology model of human systemic glucose dynamics.
Mori-Anai K; Tashima Y; Nakada T; Nakamaru Y; Takahata T; Saito R
Biopharm Drug Dispos; 2020 Nov; 41(8-9):352-366. PubMed ID: 33085977
[TBL] [Abstract][Full Text] [Related]
3. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T
Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006
[TBL] [Abstract][Full Text] [Related]
4. Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.
Trujillo JM; Nuffer WA
Pharmacotherapy; 2017 Apr; 37(4):481-491. PubMed ID: 28102030
[TBL] [Abstract][Full Text] [Related]
5. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Davidson JA; Kuritzky L
Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
[TBL] [Abstract][Full Text] [Related]
6. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Kosiborod M; Cavender MA; Fu AZ; Wilding JP; Khunti K; Holl RW; Norhammar A; Birkeland KI; Jørgensen ME; Thuresson M; Arya N; Bodegård J; Hammar N; Fenici P;
Circulation; 2017 Jul; 136(3):249-259. PubMed ID: 28522450
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus.
Mondick J; Riggs M; Kaspers S; Soleymanlou N; Marquard J; Nock V
J Clin Pharmacol; 2018 May; 58(5):640-649. PubMed ID: 29251772
[TBL] [Abstract][Full Text] [Related]
8. The role of SGLT2 inhibitors in managing type 2 diabetes.
Tat V; Forest CP
JAAPA; 2018 Jun; 31(6):35-40. PubMed ID: 29846314
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
10. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
Chu C; Lu YP; Yin L; Hocher B
Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
[TBL] [Abstract][Full Text] [Related]
11. Polypharmacology of clinical sodium glucose co-transport protein 2 inhibitors and relationship to suspected adverse drug reactions.
Matharu K; Chana K; Ferro CJ; Jones AM
Pharmacol Res Perspect; 2021 Oct; 9(5):e00867. PubMed ID: 34586753
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Benefit of SGLT2 Inhibitors in the Therapeutics of Diabetes Mellitus: A Close Look beyond the Horizon.
Ren DY; Zhang Y
Curr Drug Targets; 2018; 19(9):1051-1057. PubMed ID: 29848274
[TBL] [Abstract][Full Text] [Related]
13. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
J Pharmacol Sci; 2016 Mar; 130(3):159-69. PubMed ID: 26970780
[TBL] [Abstract][Full Text] [Related]
14. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
Carlson CJ; Santamarina ML
Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721
[TBL] [Abstract][Full Text] [Related]
15. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
Brady JA; Hallow KM
J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
[TBL] [Abstract][Full Text] [Related]
16. SGLT-2 Inhibitors: A Novel Mechanism in Targeting Glycemic Control in Type 2 Diabetes Mellitus.
Nathan KT; Ahmed-Sarwar N; Werner P
Consult Pharm; 2016 May; 31(5):251-60. PubMed ID: 27178654
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
Schubert A; Buchholt AT; El Khoury AC; Kamal A; Taieb V
Curr Med Res Opin; 2017 Jun; 33(6):1155-1163. PubMed ID: 28323512
[TBL] [Abstract][Full Text] [Related]
18. Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors.
Wilcox CS
Hypertension; 2020 Apr; 75(4):894-901. PubMed ID: 32114848
[TBL] [Abstract][Full Text] [Related]
19. SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.
Scheen AJ
Expert Opin Drug Saf; 2015; 14(12):1879-904. PubMed ID: 26513131
[TBL] [Abstract][Full Text] [Related]
20. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
Reed JW
Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
